Overview

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Status:
Active, not recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

Open label multicentric phase II randomized trial, using high throughput genome analysis as a therapeutic decision tool, which aims at comparing a targeted treatment administered according to the identified molecular anomalies of the tumor with maintenance chemotherapy (targeted substudy 1) as well as immunotherapy with maintenance chemotherapy in patients without actionable genomic alterations or non eligible to substudy 1 (immune substudy 2).

Phase:

Phase 2

Details

Lead Sponsor:

UNICANCER

Collaborators:

AstraZeneca
Fondation ARC

Treatments:

Albumin-Bound Paclitaxel
Alkylating Agents
Bevacizumab
Bicalutamide
Capecitabine
Carboplatin
Cisplatin
Cyclophosphamide
Docetaxel
Doxorubicin
Durvalumab
Epirubicin
Gemcitabine
Liposomal doxorubicin
Methotrexate
Mitomycin
Mitomycins
Olaparib
Paclitaxel
Taxane
Vinblastine
Vinca Alkaloids
Vincristine
Vinorelbine